136 related articles for article (PubMed ID: 29393183)
1. Chemotherapy of Oligodendrogliomas.
Drappatz J; Lieberman F
Prog Neurol Surg; 2018; 31():152-161. PubMed ID: 29393183
[TBL] [Abstract][Full Text] [Related]
2. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
Levin VA
Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
[No Abstract] [Full Text] [Related]
3. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M;
Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396
[TBL] [Abstract][Full Text] [Related]
4. Low-grade and anaplastic oligodendroglioma.
Van Den Bent MJ; Bromberg JE; Buckner J
Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study.
Ahluwalia MS; Xie H; Dahiya S; Hashemi-Sadraei N; Schiff D; Fisher PG; Chamberlain MC; Pannullo S; Newton HB; Brewer C; Wood L; Prayson R; Elson P; Peereboom DM
J Neurooncol; 2015 Mar; 122(1):111-9. PubMed ID: 25534576
[TBL] [Abstract][Full Text] [Related]
6. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
Rinne ML; Wen PY
Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
[No Abstract] [Full Text] [Related]
7. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
8. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
[TBL] [Abstract][Full Text] [Related]
9. Procarbazine, lomustine and vincristine or temozolomide: which is the better regimen?
Lassman AB
CNS Oncol; 2015; 4(5):341-6. PubMed ID: 26544062
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
[TBL] [Abstract][Full Text] [Related]
11. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
Anderson MD; Gilbert MR
Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic strategies for the management of gliomas].
Hottinger AF; Stupp R
Rev Neurol (Paris); 2008; 164(6-7):523-30. PubMed ID: 18565350
[TBL] [Abstract][Full Text] [Related]
13. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in the use of chemotherapy in brain tumours.
van den Bent MJ; Hegi ME; Stupp R
Eur J Cancer; 2006 Mar; 42(5):582-8. PubMed ID: 16427778
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of Diffuse Astrocytoma (WHO grade II) in Adults.
Narita Y
Prog Neurol Surg; 2018; 31():145-151. PubMed ID: 29393182
[TBL] [Abstract][Full Text] [Related]
16. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?
Siker ML; Chakravarti A; Mehta MP
Crit Rev Oncol Hematol; 2006 Nov; 60(2):99-111. PubMed ID: 17027279
[TBL] [Abstract][Full Text] [Related]
17. Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature.
Sorge C; Li R; Singh S; Reddy AT; Solomon DA; Perry A; Friedman GK
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28696020
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeted therapies and chemotherapy in malignant gliomas.
Brandsma D; van den Bent MJ
Curr Opin Oncol; 2007 Nov; 19(6):598-605. PubMed ID: 17906459
[TBL] [Abstract][Full Text] [Related]
19. Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas.
Levin VA; Hess KR; Choucair A; Flynn PJ; Jaeckle KA; Kyritsis AP; Yung WK; Prados MD; Bruner JM; Ictech S; Gleason MJ; Kim HW
Clin Cancer Res; 2003 Mar; 9(3):981-90. PubMed ID: 12631596
[TBL] [Abstract][Full Text] [Related]
20. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]